Perspectives on Regulatory T Cell Therapies.

Area of Science:

• Immunology
• Cell Biology

Background:

• CD4+ CD25+ FOXP3+ regulatory T (Treg) cells are vital in preventing autoimmune and graft-versus-host disease.
• Treg cell therapies hold promise for establishing immune tolerance.
• Differentiating human Treg cells from activated effector T cells is challenging due to overlapping markers like FOXP3.

Purpose of the Study:

• To review the role of Glycoprotein-A repetitions predominant (GARP) as a specific marker for human Treg cells.
• To explore GARP's function in maintaining the Treg cell regulatory network.
• To discuss the implications of GARP for developing novel Treg cell-based therapies.

Main Methods:

• Literature review focusing on Treg cell biology and marker identification.
• Analysis of the role of GARP in Treg cell function and differentiation.
• Discussion of GARP's potential as a therapeutic target.

Main Results:

• Glycoprotein-A repetitions predominant (GARP), also known as LRRC32, is identified as a Treg cell-specific molecule.
• GARP acts as a key regulator, maintaining FOXP3 expression through a positive feedback loop.
• GARP represents a promising target for developing specific Treg cell therapies.

Conclusions:

• GARP is a crucial safeguard for the human Treg cell regulatory network.
• Targeting GARP offers new avenues for molecular and cellular therapies in autoimmunity and graft-versus-host disease.
• The identification of GARP facilitates the development of more effective Treg cell-based treatments.